Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial

BACKGROUND: In the phase 2, randomized, double-blind STRIVE trial, enzalutamide significantly reduced the risk of prostate cancer progression or death versus bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and nonmetastatic CRPC (nmCRPC). The objective of this p...

Descripción completa

Detalles Bibliográficos
Autores principales: Penson, David F., Armstrong, Andrew J., Concepcion, Raoul S., Agarwal, Neeraj, Olsson, Carl A., Karsh, Lawrence I., Dunshee, Curtis J., Duggan, William, Shen, Qi, Sugg, Jennifer, Haas, Gabriel P., Higano, Celestia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184266/
https://www.ncbi.nlm.nih.gov/pubmed/34621011
http://dx.doi.org/10.1038/s41391-021-00465-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184266/
https://www.ncbi.nlm.nih.gov/pubmed/34621011
http://dx.doi.org/10.1038/s41391-021-00465-7

Ejemplares similares